VSV-02 Compassionate Use in Advanced Solid Tumors

This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by Shanghai Rongrui Pharmaceutical Technology Co., Ltd. The main purpose of this open-label, single-arm study is to assess the preliminary effectiveness and safety of VSV-02 when it is given through two routes: directly into a vein (intravenously) and by injection directly into the tumor (intratumorally). Patients will receive the treatment on the first day of each 3-week

Trial Details

NCT ID
NCT07260591
Phase
PHASE1
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • VSV-02 Injection
Locations (sample)
  • Xinxiang, Henan, China|35.19033,113.80151

Key Eligibility Criteria

  • Voluntary signed informed consent.
  • Age ≥ 18 years.
  • Histologically or cytologically confirmed advanced solid tumor (e.g., melanoma, head and neck squamous cell carcinoma, cervical cancer, osteosarcom…
  • Disease progression after at least two prior lines of standard therapy (including targeted therapy), or for whom no standard therapy exists or is m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →